Menten AI CEO Hans Melo Showcases Generative AI Breakthroughs at Global Conferences

Our CEO, Hans Melo, represented Menten AI at both BioEurope and NextGen Biomed, where he engaged with the world’s leading scientific minds and biotech innovators. At NextGen Biomed, Hans took the stage as a featured speaker to discuss the topic of De novo design of oral and cell permeable peptide using generative AI.

The core of Hans’s presentations centered on our proprietary MAUD 1.0 platform. Following its successful launch this year, MAUD 1.0 has become the cornerstone of our efforts to:

• Revolutionize Design: Utilizing generative AI to create peptides with superior oral bioavailability.
• Enhance Permeability: Solving the complex challenge of delivering potent peptides directly into the cell.
• Empower Partners: Helping our strategic partners reach their R&D goals faster and with greater percision.

Why It Matters

For Menten AI, these conferences are more than just speaking engagements—they are vital opportunities to collaborate with the scientific community. By spreading awareness of new trends in the peptide therapeutics space, we continue to bridge the gap between advanced computational design and life-changing clinical applications.

‍